Obesity and tobacco abuse, widely recognised as serious health hazards, are increasing in prevalence. Obesity is associated with numerous metabolic complications such as dyslipidemia, type 2 diabetes and cardiovascular diseases. Smoking is a high risk factor for hypertension, lung carcinoma and various other health related problems. The agents that have been used for the treatment of obesity include dexfenfluramine, phentermine, sibutramine and orlistat. Currently, the options for smoking cessation are nicotine patches, gum, lozenges and bupropion. As many of these drugs have serious adverse effects or are unsuitable for maintenance therapy, the search for a novel drug continues.

Rimonabant appears to be a promising drug in an entirely new class called selective cannabinoid (CB1) receptor antagonists. Recent studies have demonstrated the beneficial effects of rimonabant in tackling obesity, smoking cessation and metabolic syndrome. The drug may be approved for treatment of obesity and smoking cessation. Ongoing studies may provide information on its other clinical uses.

Rimonabant has demonstrated a long duration of action (8 hours) and good oral bioavailability.Read more about rimonabant